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Summary 
 
Patient reported outcome (PRO) measures are increasingly being used in epidemiological 
studies, health services research and in clinical trials to evaluate therapeutic interventions 
from the patient‟s perspective. In MS, where evaluations of treatments are becoming 
increasingly important, outcome measures that are rigorous and appropriate to patients are 
needed. This article examines the value of PRO measures in MS, the criteria of evaluating 
such measures, and provides a brief description of MS-specific PRO measures that are 
currently available.  
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Introduction 
 
Patient reported outcome (PRO) is an umbrella term referring to questionnaires, interviews 
and other related methods of assessing health, illness and benefits of health care interventions 
from the patient's perspective. For people with chronic illnesses such as MS, these measures 
capture the diverse impact of illnesses on their day-to-day lives.  
 
Over the past two decades, outcome measurement in MS has relied extensively on the 
Expanded Disability Status Scale (EDSS) [1] as a measure of disease activity.  However, the 
EDSS is heavily weighted towards mobility and does not reflect patients‟ problems in other 
areas of health. Furthermore, the EDSS was developed before psychometric methods became 
familiar to clinicians, was not based on recognised techniques of scale constructions [2], and 
has limited measurement properties [3,4]. Most importantly, it is rated by neurolgists and may 
not adequately reflect patients‟ own perceptions of the impact of their MS.  
 
This paper aims to highlight: 1) the importance of PRO measures 2) criteria for selecting PRO 
measures and 3) a brief review of currently available PRO measures in MS. 
 
What are PRO measures and why are they important?  
 
A simple but useful classification considers health outcomes to be either physician or patient-
based.  
 
Physician-based outcomes are the traditional biomedically defined outcomes. In MS, MRI 
and relapse rate are good examples of physician-based outcomes. Although these assessments 
are in no doubt important, they only partly address partly address patients‟ concerns [5], and 
provide an incomplete picture of the disease impact of MS from the patients‟ perspectives. 
 
Patient-based, or patient-reported outcomes (PROs), on the other hand, are concerned with the 
consequences of disease and treatment that are considered important to patients. As health 
care providers place increasing emphasis on evidence-based practice, PRO measures have 
become increasingly important, as they measure outcomes that matter to patients. There is 
evidence that MS patients and physicians differ in which domains of health are the most 
important [6]. As new treatments for MS are aimed at altering its natural history or modifying 
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its impact, PRO measures are essential in a comprehensive evaluation of therapeutic 
effectiveness.  
 
Although all PRO instruments address some aspect of the patient's subjective experience of 
their health, there is lack of concensus with regards to what PROs actually measure. For 
example, there is little consistency of use or agreement in the meaning of terms such as 
'quality of life', 'health-related quality of life', 'health status', 'functional status' and 'functional 
well-being'. However, patient-based outcome measures most often focus on what is 
commonly referred to as “health-related quality of life” (HRQoL). 
 
Health-related quality of life (HRQoL) 
 
Although many definitions for HRQoL have been proposed, the most accepted definition is 
“the patient’s subjective perception of the impact of his disease and its treatment(s) on his 
daily life, physical, psychological and social functioning and well-being” [7]. This definition 
of HRQL has as a common basis with the definition of health given by the WHO in 1948: 
“Health, is a state of complete physical, mental, and social well-being and not merely the 
absence of disease”[8]. Furthermore, it is generally accepted that while “quality of life 
(QoL)” is to do with a much broader concept, including community, work and family 
domains [9], “HRQoL” concerns those domains that are most affected by disease, injury or 
treatment [10]. 
 
Several characteristics of HRQoL have also been proposed.  These include:  
multidimensionality, subjectivity, and self-administration.   
 
First, HRQoL is assumed to consist of several dimensions. Again, although there are no 
consensus as to the number and nature of the dimensions, it is generally assumed that HRQoL 
consists of at least the physical and psychological dimensions [11]. This distinction is 
empirically supported by many studies, for example, the analyses of the Medical Outcomes 
Short-form Health Survey (SF-36) [12]. More recently, in addition to the physical and 
psychological dimensions, the inclusion of the participation (role and social) dimension has 
been proposed [11]. 
 
The second and third characteristics are closely linked. HRQoL is essentially a subjective 
concept that must be evaluated from the perspective of the patient. The final characteristic is 
self-administration. Because HRQoL is subjective, patients themselves are most suited to 
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complete the measures themselves, and there is concern that external administration may 
somehow influence patient‟s true responses.   
 
 
Are there different types of patient-based outcome measures? 
 
Broadly speaking, there are two types of patient-based outcome measures:  
 
Generic measures are those that are designed to be broadly applicable across different types 
and severity of disease, medical interventions, and demographic and cultural groups so as to 
permit comparisons across studies. The Medical Outcome Study Short From-36 [13] is a 
well-known example, and one that has also been used in many studies involving MS patients. 
For example, in one study, MS patients and Parkinson‟s disease patients had significantly 
worse health than the general population on all eight domains measured by the SF-36 [14].  
 
Disease-specific measures are designed to reflect clinically relevant issues for a specific 
disease.  They are intended to have very relevant content, with the items in the questionnaire 
being developed specifically to assess the impact of the particular disease. Several disease-
specific measures for MS patients have now been developed. These are examined in a later 
section. 
 
Although generic measures have the advantage of enabling comparisons across diseases, it is 
increasingly recognised that they do not cover some areas of outcome that are highly relevant 
in specific diseases [15], and may have limited responsiveness [16]. Furthermore, the SF-36 
has psychometric limitations when used in MS. These include significant floor and ceiling 
effects [17], limited responsiveness [17], underestimation of mental health problems [18], and 
a failure to satisfy assumptions for generating summary scores [19].   
 
How can you evaluate patient-based outcome measures? 
 
Guidance on the evaluation of PRO instruments has been offered by the Division of Drug 
Marketing, Advertising, and Communications (DDMAC) of the Federal Drug Agency (FDA), 
as well as being available recently in a draft guidance document from the FDA [20]. 
According to the draft guidance document, PRO instrument development and modification 
process include the establishment of conceptual framework and identification of the intended 
application, instrument development, the assessment of measurement properties and 
instrument modification issues. In particular, for potential users of an PRO measures, the 
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measurement properties are particularly important in the selection of measures.   These 
measurement properties are based on psychometric theory, which is a scientifically rigorous 
field that is concerned with the science of assessing the measurement characteristics of 
instruments. In general, there are six psychometric properties that should be examined: data 
quality, scaling assumptions, acceptability, reliability, validity and responsiveness.   
 
Insert Table 1 here 
 
 
 
 Indicators of data quality such as item non-response and missing scale scores, 
determine the extent to which an instrument can be used successfully in a clinical 
setting.  
 Scaling assumptions test whether items are correctly grouped into scales, and if the 
items can be summed without weighting or standardisation to produce a score.  
 Acceptability is concerned with the score distribution of the scale, and whether it 
represents the true distribution of the construct being measured in the sample.  
 The reliability of an instrument is defined as the extent to which it is free from 
random error. A reliable measure produces results that are accurate, consistent, stable 
over time and reproducible. Test-retest reliability (stability of scores over time when 
no change has occurred in the concept of interest) and internal consistency (the 
intercorrelations of items in the same domain, measured by the internal consistency 
statistic, e.g. the Cronbach‟s alpha) are two of the most frequently examined types of 
reliability.  
 Validity can be broadly defined as the extent to which an instrument measures the 
concept it purports or is intended to measure. Face validity (the extent to which a 
measure appears on the surface to measure what it is suppose to measure), content-
related validity (whether items and response options are relevant and are 
comprehensive measures of the domain or concept), construct-related validity 
(whether relationships among items, domains, and concepts conform to what is 
predicted by the conceptual framework for the PRO instrument itself and its 
validation hypotheses) and predictive validity (whether items and response options 
are relevant and are comprehensive measures of the domain or concept) are 
frequently examined. 
 Responsiveness is the ability of an instrument to measure clinically important change 
over time, and is essential when evaluating the relative benefits of different 
interventions.  
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What measures have been developed for MS? 
 
A number of MS-specific measures have been developed.  Those measures whose original 
version is in English include: the Multiple Sclerosis Quality of Life-54 (MSQOL-54) [21], the 
Functional Assessment of MS (FAMS) [22], the MS Quality of Life Inventory (MSQLI) [23], 
the Multiple Sclerosis Impact Scale (MSIS-29) [24] and the Leeds Multiple Sclerosis Quality 
of Life (Leeds MSQoL) [25]. Table 2 reports the summary characteristics of these measures. 
Brief descriptions of each of the measures are also reported below. 
 
Insert Table 2 here 
 
 
Multiple Sclerosis Quality of Life-54 (MSQOL-54) 
 
MSQOL-54 is a MS-specific quality of life measure consisting of 54 items. This measure is 
based on the SF-36, but supplemented with 18 additional items in the following areas: health 
distress (four items), sexual function (four items), satisfaction with sexual function (one item), 
overall quality of life (two items), cognitive function (four items), energy (one item), pain 
(one item) and social function (one item).  
 
Functional Assessment in MS (FAMS) 
 
Cella et al (1996) developed a quality of life instrument consisting of 28 items from the 
general version of the Functional Assessment of Caner Therapy quality of life instrument, 
plus 60 items generated by patients, care providers and literature review. Using principal 
components analyses and Rasch analyses, items were reduced to 44 with subscales: mobility, 
symptoms, emotional well-being (depression), general contentment, thinking/fatigue, and 
family/social well-being. Fifteen initially rejected questions were then added back as 
miscellaneous (unscored) questions for their potential clinical and empirical value, resulting 
in a final 59-item questionnaire. 
 
MS Quality of Life Inventory (MSQLI) 
 
The MSQLI is a battery consisting of 10 individual scales (SF-36, Modified Fatigue Impact 
Scale (MFIS); MOS Pain Effects Scale (PES), Sexual Satisfaction Scale (SSS), Bladder 
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Control Scale (BLCS), Bowel Control Scale (BWCS), Impact of Visual Impairment Scale 
(IVIS), Perceived Deficits Questionnaire (PDQ). This provides a quality of life measure that 
is both generic and MS-specific [26]. Some scales also have a short-form.  Each of the 
individual scales generates a separate score, and there is no global composite combining all 
the scales into a single score. 
  
 Multiple Sclerosis Impact Scale (MSIS-29) 
 
The Multiple Sclerosis Impact Scale (MSIS-29) is a measure
 
of the physical and 
psychological impact of MS from the patient‟s perspective. The total scale consists of 29 
items, while the physical scale consists of 20 items, and the psychological scale consists of 9 
items. The scale was developed from in-depth interviews of a community sample of people 
with MS. 
 
 
The Leeds Multiple Sclerosis Quality of Life (Leeds MSQoL) 
 
Leeds MSQOL is an eight-item scale developed from focus group sessions with people with 
MS.  Twenty-five initial items were reduced using traditional psychometric methods and 
Rasch measurement model. The instrument is brief and measures a construct related to well-
being. 
 
Other scales developed for people with MS include the RAYS Scale [28] and the Disability 
and Impact Profile (DIP) [29]. The RAYS  Scale is a 50-item questionnaire measuring similar 
dimensions to MSQLI, MQOL-54 and FAMS. The DIP is a 39 item measure in which 
patients indicate both their level of disability and the importance of the disability to the 
patient. 
 
 
 
How can you select which instrument to use? 
 
It can be difficult for health professionals to choose between the various MS-specific scales 
that are available. It may be tempting to choose a measure based on practical reasons, for 
example, selecting a measure because it is short with few items. However, it is recommended 
that the choice of patient-based outcome measures be evidence-based; that is, how well the 
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measure meets the psychometric criteria discussed above. One method is to conduct a head-
to-head comparison of various measures and selecting the measure with the best psychometric 
properties. There are now several studies that have attempted to provide such data (eg. [30, 
31]).  
 
Several other review articles on PRO measures in MS have now also been published [eg. 
32,33,34] some of which have compared the measurement properties of various measures. For 
example, Nicholl [32], compared the measurement properties of several measures used in MS 
and concluded that FAMS was the most superior.  These reviews also highlight the fact that 
PRO measures are useful but that there is a lack of data on comparison of responsiveness of 
measures [33], and that further work is required to decide which scale is most suited to which 
purpose [34]. 
 
Of course, that is not to say that a brief, user-friendly, and cost effective, measure will be 
more suitable for use in clinical practice. But in reality, the use of patient-based outcome 
measures in clinical practice for people with MS is still limited. In a recent review  [35], the 
cultural, practical and methodological reasons behind this were discussed. These included 
clinicians‟ lack of knowledge of patient-based outcomes, and the logistic and financial 
implications of administering, processing and scoring the measures. An additional important 
point worth mentioning is the fact that currently, the confidence intervals around most 
patient-based outcome scores are too wide for reliable and valid individual patient clinical 
decision-making.  Newer psychometric approaches, such as Rasch analysis [36], offer the 
ability to construct interval-level measurements from ordinal-level scales (that are currently 
derived from existing patient-based outcome measures data). There is now at least one 
measure for use with people with MS that has been developed guided by Rasch analysis [37]. 
The use of such newer psychometric approaches are also exciting from the point of view that 
it can form a basis of computerised administration of measures (computer adaptive testing) 
[38]. 
 
Conclusion 
 
In conclusion, PRO measures are increasingly recognised as being central in health-care 
evaluation as they offer patients' perspectives on the quality of their health. It is important that 
such instruments are scientifically rigorous to ensure that interventions for MS are accurately 
evaluated. This is imperative as an increasing number of clinical trials are being conducted to 
investigate novel therapeutic strategies for MS [39]. Comprehensive evaluations of the 
psychometric properties of available measures, ideally in comparison with each other, will 
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assist in the selection of the most appropriate measure. Although the use of PRO is still not 
widespread within clinical practice, this may change overtime, as clinicians become more 
familiar with the importance of obtaining patient-derived data, and newer psychometric 
approaches offer potentially new and simpler ways of administering the measures (eg use of 
computer adaptive testing). This will also enable PRO measures to be utilised for individual 
patient monitoring within routine clinical practice.  
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Table 1. Examples of psychometric criteria often used for determining the adequacy 
of HRQoL scales 
 
Psychometric property Criterion for adequacy 
Data quality Missing item data < 10% 
High % computable scale scores 
Scaling assumptions Similar response option frequency distributions 
Similar mean scores and variances 
Acceptability Scores span the full scale range 
Mean scores near midpoint 
Reliability Cronbach‟s alpha > 0.80 
Validity  
 Convergent and discriminant 
 validity 
High correlations between scales measuring similar 
concepts 
Low correlations between scales measuring 
dissimilar 
Responsiveness Large (0>0.80) to moderate effect sizes (= 0.50) 
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Table 2 Characteristics of some MS-specific HRQoL instruments 
 
 MSQOL-54 FAMS MSQLI MSIS-29 Leeds MSQoL 
Original 
publication 
Vickery et al., 1995 Cella et al., 1996 Ritvo et al 1997 Hobart et al., 2001 Ford et al., 2001 
No of items 54 59 (of which 44 are scored) 137 (80 with abbreviated scales) 29 8 
Dimensions  SF-36 and items in the following 
areas: health distress, sexual 
function, satisfaction with sexual 
function, overall quality of life, 
cognitive function, energy, pain 
and social function 
mobility, symptoms, emotional 
well-being (depression),  
general contentment, 
thinking/fatigue, family/social well-
being 
9 scales including 
SF-36, 
Modified Fatigue Impact Scale, MOS 
Pain Effects, Sexual Satisfaction Scale, 
Bladder Control Scale, 
Bowel Control Scale, 
Impact of Visual Impairment, 
Perceived Deficits Questionnaire, 
Mental Health Inventory, 
MOS Social Support Scale 
 
physical and psychological unidimensional measure of well-being 
Reliability Internal consistency  
(0.75-96); 
Test-retest (0.66-96) 
[21] 
Internal consistency (0.82-96); 
Test-retest (0.85-91) 
[22] 
Internal consistency (0.75-0.97)  
[26] 
Internal consistency (0.91-0.96); Test-
retest (0.87-0.94) [27] 
Internal consistency (0.79); 
Test-retest (0.85)  
[25] 
 
Validity Correlations among subscales 
conformed to predicted 
relationships among their 
underlying constructs 
 
Significant associates between 
MSQOL-54 scales and degree of 
multiple sclerosis symptom 
severity in the prior year, level of 
ambulation, employment 
limitations due to health, 
admission to hospital in the 
previous year, and depressive 
symptoms.[21] 
 
Construct validity of the scales were 
supported by the predictable 
patterns of correlations among its 
subscales, and by relationships 
between its subscales and other 
measures (SF-36, Hospital Anxiety 
and Depression Scale, Multiscale 
Depression Inventory). FAMS 
subscales correlated predictably 
with self-assessed physical 
impairment (Eastern 
Cooperative Oncology Group  
Performance Status Rating), and for 
a subsample, mobility scores were 
correlated with EDSS and Scripps 
Neurologic Rating Scale. 
[22] 
 
 
Construct validity supported of both the 
generic scale (SF-36) and the symptom-
specific measures were supported by 
intercorrelations among scales. 
 
As expected, most symptom-specific 
measures correlated relatively weakly as 
expected with objective measures of 
impairment, as there was little 
correspondence between most symptom-
specific scales and the impairment 
measures. One exception to this were 
the Impact of Visual Impairment Scale, 
which correlated moderately with the 
expected objective measures (ie visual 
acuity, Visual and Brainstem FSS, and 
EDSS)  
[26] 
 
Direction, magnitude and pattern of 
correlations are consistent with 
predictions.  
 
For example, MSIS-29 physical scale 
correlated most highly with the FAMS 
mobility scale, the SF-36 physical 
functioning scale and the BI, and least 
with the EQ-5D anxiety/depression 
dimension, the SF-36 role emotional 
scale and the FAMS family/social 
well-being scale.  
 
Mean MSIS-29 scores for people who 
were retired due to MS were 
significantly higher than for those 
who were still employed [27] 
 
Correlations  with well-being (0.83) 
than to physical function (–0.39)  
 
LMSQoL able to detect  significant 
difference between the „early relapsing 
remitting‟ plus „benign‟ groups and the „progressive‟ 
groups [25] 
 
 
